文献速递肝病消化道出血

利伐沙班预防肝硬化门静脉高压并发症:CIRROXABAN研究

Rivaroxaban to prevent complications of portal hypertension in cirrhosis: The CIRROXABAN study.
PubMed 文献 · J Hepatol · 2025-07-19

这项随机、双盲、安慰剂对照、多中心试验纳入90例肝硬化伴门静脉高压及中度肝功能障碍(Child-Pugh评分7-10)患者,评估利伐沙班10 mg每日一次共24个月的效果。中位随访10.1个月,主要复合终点在安慰剂组23例(46.9%)vs 利伐沙班组11例(26.8%),log-rank p=0.058;利伐沙班组非门静脉高压相关出血事件更常见(36.6% vs 14.3%),但大出血无显著差异。

要点

  • 利伐沙班10 mg每日一次治疗24个月,主要终点事件安慰剂组46.9% vs 利伐沙班组26.8%(log-rank p=0.058)。
  • Child-Pugh B7亚组事后分析显示利伐沙班可能有益(HR 0.258;95%CI 0.074-0.900)。
  • 非门静脉高压相关出血利伐沙班组36.6% vs 安慰剂组14.3%(RR 2.56;95%CI 1.16-5.67),大出血无显著差异。

核心结论

  • 在肝硬化伴中度肝功能障碍患者中,利伐沙班可能改善无门静脉高压并发症生存,且未显著增加大出血风险。
  • 总体队列主要终点降低未达统计学显著,Child-Pugh B亚组事后分析观察到潜在获益,但鉴于亚组分析的探索性性质,这些发现应谨慎解读。
  • 利伐沙班组非门静脉高压相关出血事件更常见,但严重出血事件未增加。

研究设计与样本

  • 随机、双盲、安慰剂对照、多中心试验,纳入肝硬化、门静脉高压及中度肝功能障碍(Child-Pugh评分7-10)患者。
  • 参与者接受利伐沙班10 mg每日一次或安慰剂治疗24个月。
  • 主要复合终点为发生门静脉高压相关并发症或死亡/肝移植,以先发生者为准。
  • 分析采用改良意向性治疗和符合方案两种方法。
  • 共纳入90例患者(安慰剂组49例,利伐沙班组41例)。

主要发现

  • 中位随访10.1个月,34例达到主要终点:安慰剂组23例(46.9%)vs 利伐沙班组11例(26.8%)。
  • 1年和2年无主要终点累计生存概率:安慰剂组54.4%和43.0%,利伐沙班组78.7%和67.1%(log-rank p=0.058)。
  • Child-Pugh B7评分患者(n=55)事后分析中,利伐沙班显示潜在有益效应(HR 0.258;95%CI 0.074-0.900)。
  • 符合方案分析(安慰剂组41例,利伐沙班组37例)中,主要事件安慰剂组19例(46.3%)vs 利伐沙班组9例(24.3%)(HR 0.463;95%CI 0.209-1.024)。
  • 非门静脉高压相关出血事件利伐沙班组更常见(36.6% vs 14.3%;RR 2.56;95%CI 1.16-5.67),大出血事件无显著差异。

临床怎么用

  • 作者认为,本研究为利伐沙班用于预防肝硬化伴门静脉高压患者肝脏失代偿提供了新证据。
  • 作者指出,观察到的失代偿事件减少与既往关于抗凝治疗在肝硬化中获益的发现一致,提示利伐沙班在该人群中可能具有治疗作用。
  • 作者强调,需要进一步研究以确定兼顾疗效与出血风险的最佳给药策略。

局限性

  • 总体队列主要终点降低未达统计学显著(log-rank p=0.058)。
  • Child-Pugh B亚组获益来自事后分析,鉴于亚组分析的探索性性质,这些发现应谨慎解读。
  • 利伐沙班组非门静脉高压相关出血事件更常见。
  • 需要进一步研究以确定兼顾疗效与出血风险的最佳给药策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Previous studies suggest that anticoagulation may reduce the risk of portal hypertension (PHT)-related complications and improve survival in patients with cirrhosis. This study aimed to evaluate the efficacy and safety of the direct oral anticoagulant rivaroxaban in patients with cirrhosis. METHODS: This was a randomized, double-blind, placebo-controlled, multicenter trial involving patients with cirrhosis, PHT, and moderate liver dysfunction (Child-Pugh score 7-10). Participants received either rivaroxaban 10 mg daily or placebo for 24 months. The primary composite endpoint was the development of a PHT-related complication or death/liver transplantation, whichever occurred first. Analyses were conducted using both modified intention-to-treat and per-protocol approaches. RESULTS: A total of 90 patients were enrolled (49 placebo, 41 rivaroxaban). After a median follow-up of 10.1 months, 34 patients reached the primary endpoint: 23 (46.9%) in the placebo group vs. 11 (26.8%) in the rivaroxaban group. The cumulative probability of survival free from the primary endpoint at 1 and 2 years was 54.4% and 43.0% in the placebo group, compared to 78.7% and 67.1% in the rivaroxaban group (log-rank p = 0.058). In a post hoc analysis of patients with Child-Pugh B7 scores (n = 55), rivaroxaban showed a potentially beneficial effect (hazard ratio 0.258; 95% CI 0.074-0.900). In the per-protocol analysis (41 placebo, 37 rivaroxaban), the primary event occurred in 19 patients (46.3%) in the placebo group vs. 9 (24.3%) in the rivaroxaban group (hazard ratio 0.463; 95% CI 0.209-1.024). Non-PHT-related bleeding events were more frequent in the rivaroxaban group (36.6% vs. 14.3%; relative risk 2.56; 95% CI 1.16-5.67). However, there were no significant differences in major bleeding events. CONCLUSIONS: In patients with cirrhosis and moderate liver dysfunction, rivaroxaban may improve PHT complication-free survival without significantly increasing the risk of major bleeding. IMPACT AND IMPLICATIONS: This study provides novel evidence supporting the potential use of rivaroxaban to prevent liver decompensation in patients with cirrhosis and portal hypertension. The observed reduction in decompensation events is consistent with previous findings on the benefits of anticoagulation in cirrhosis, suggesting a possible therapeutic role for rivaroxaban in this population. Although the reduction in the primary endpoint did not reach statistical significance in the overall cohort, a potential benefit was observed in a post hoc analysis of patients with Child-Pugh B cirrhosis. However, these findings should be interpreted with caution given the exploratory nature of the subgroup analyses. Non-portal hypertension-related bleeding events were more frequent in patients receiving rivaroxaban, though severe bleeding events were not increased. These results highlight the need for further studies to determine optimal dosing strategies that balance efficacy with bleeding risk. CLINICALTRIALS: GOV: NCT02643212. EUDRACT NUMBER: 2014-005523-27.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Puente Á, Turón F, Martínez J, et al. Rivaroxaban to prevent complications of portal hypertension in cirrhosis: The CIRROXABAN study. J Hepatol. 2025. PMID: 40691992. doi:10.1016/j.jhep.2025.06.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。